The Gates Foundation Trust has sold its remaining Microsoft shares after over 25 years, while also adding a new position in West Pharmaceutical Services, a healthcare stock with strong growth potential and a history of consistent dividend increases. This move signals a shift in the foundation's investment strategy and highlights West Pharmaceutical's promising future as a potential "Dividend King."
The Gates Foundation Trust's recent action of completely divesting from Microsoft and investing in West Pharmaceutical Services highlights a strategic shift towards a potentially high-growth, dividend-yielding healthcare stock. For long-term investors, West Pharmaceutical Services merits attention, given its potential for becoming a Dividend King and its forecasted earnings growth of 14% to 15% annually. This move suggests an opportunity to capitalize on both growth and dividend income in a relatively recession-resistant industry.